Our previous study of a novel linear vimentin-binding minipeptide and virus nanoparticles for CSV-targeted tumor-specific therapy indicated that vimentin is expressed on the surface of cancer stem cells (CSCs) and is internalized upon contact with specific ligands [7, 8]. The gene discussed is VIM; the disease is neoplasm.